Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells
Béatris Mastelic-Gavillet, Blanca Navarro Rodrigo, Laure Décombaz, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 170

Showing 1-25 of 170 citing articles:

The adenosine pathway in immuno-oncology
Bertrand Allard, David Allard, Laurence Buisseret, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 10, pp. 611-629
Closed Access | Times Cited: 405
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion
Paola De Cicco, Giuseppe Ercolano, Angela Ianaro
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 259
CD39/CD73/A2AR pathway and cancer immunotherapy
Chenglai Xia, Shuanghong Yin, Kenneth K.W. To, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 154
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
Huailiang Wu, Yue Gong, Peng Ji, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 111
Adenosine-A2A Receptor Pathway in Cancer Immunotherapy
Changfa Sun, Bochu Wang, Shilei Hao
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 98
Challenges and new technologies in adoptive cell therapy
Pengchao Zhang, Guizhong Zhang, Xiaochun Wan
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 87
Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
Eric Tu, Kelly McGlinchey, Jixin Wang, et al.
JCI Insight (2022) Vol. 7, Iss. 3
Open Access | Times Cited: 78
Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer
Lin Zhao, Yuanyuan Liu, Simiao Zhang, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 4
Open Access | Times Cited: 75
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Panagiotis-Petros Lialios, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2718-2718
Open Access | Times Cited: 48
Regulation of nucleotide metabolism in cancers and immune disorders
Eunüs S. Ali, Issam Ben‐Sahra
Trends in Cell Biology (2023) Vol. 33, Iss. 11, pp. 950-966
Open Access | Times Cited: 47
Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy
Tao Lei, Yazhuo Wang, Yuchen Zhang, et al.
Leukemia (2024)
Open Access | Times Cited: 18
CD73/adenosine dynamics in treatment-induced pneumonitis: balancing efficacy with risks of adverse events in combined radio-immunotherapies
Lena Gockeln, Florian Wirsdörfer, Verena Jendrossek
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access | Times Cited: 3
Reinvigorating exhausted CD8+ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy
Md Amir Hossain, Guilai Liu, Beiying Dai, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 1, pp. 156-201
Closed Access | Times Cited: 88
Overcoming the challenges associated with CD3+ T-cell redirection in cancer
Ajit Kumar Singh, Sundee Dees, Iqbal S. Grewal
British Journal of Cancer (2021) Vol. 124, Iss. 6, pp. 1037-1048
Open Access | Times Cited: 81
Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy
Cai Zhang, Yuxia Liu
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 76
Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them?
Justine Cinier, Margaux Hubert, Laurie Besson, et al.
Cancers (2021) Vol. 13, Iss. 8, pp. 1850-1850
Open Access | Times Cited: 76
Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells
Elham Masoumi, Leila Jafarzadeh, Hamid Reza Mirzaei, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 71
Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response
Yarden Ariav, James Ch’ng, Heather R. Christofk, et al.
Science Advances (2021) Vol. 7, Iss. 21
Open Access | Times Cited: 70
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
Dan You, Stephen Hillerman, Gregory Locke, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 1, pp. e001402-e001402
Open Access | Times Cited: 63
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Tilemachos Koutouratsas, et al.
Cancer Treatment Reviews (2022) Vol. 113, pp. 102499-102499
Closed Access | Times Cited: 60
CD8 + T cell exhaustion in anti‐tumour immunity: The new insights for cancer immunotherapy
Yijin Huang, Anna Jia, Yufei Wang, et al.
Immunology (2022) Vol. 168, Iss. 1, pp. 30-48
Open Access | Times Cited: 51
Blood monocyte-derived CD169+ macrophages contribute to antitumor immunity against glioblastoma
Hyun-Jin Kim, Jang Hyun Park, Hyeon Cheol Kim, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 45
Bispecific antibodies in multiple myeloma treatment: A journey in progress
Shih‐Feng Cho, Tsung‐Jang Yeh, Kenneth C. Anderson, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 44
The role of polyamine metabolism in remodeling immune responses and blocking therapy within the tumor immune microenvironment
Jiachun Lian, Yanfang Liang, Hailiang Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 41
CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence
Wei Wei, Zhi‐Nan Chen, Ke Wang
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12317-12317
Open Access | Times Cited: 41
Page 1 - Next Page

Scroll to top